ERBB2 and melanoma: Increased mutational load predicted a higher rate of response to anti-CTLA4 in melanoma and anti-PD-1 in lung cancer.[41, 42] There was higher TMB in TN verses HR + HER2− tumors (P-value = 3.16×10− 15).